• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Gilead Sciences

Gilead Sciences

Gilead Sciences Inc GILD 3 Star

Last Price$103.70Day Change (%)-1.44%
Open Price$104.64Day Change ($)-1.51
Day Range103.60–105.6852-Week Range72.77–116.83

As of Fri 4/24/2015 5:00:00 PM | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Gilead Announces Results From Studies Evaluating Sofosbuvir-Based Regimens in Chronic Hepatitis C Patients With Genotypes 2-5

    Gilead Announces Results From Studies Evaluating Sofosbuvir-Based Regimens in Chronic Hepatitis C Patients With Genotypes 2-5

  2. Gilead Announces Data for Investigational, All-Oral, Pan-Genotypic Three-Drug Regimen of Sofosbuvir, GS-5816 and GS-9857 for Chronic Hepatitis C

    Gilead Announces Data for Investigational, All-Oral, Pan-Genotypic Three-Drug Regimen of Sofosbuvir, GS-5816 and GS-9857 for Chronic Hepatitis C

  3. Gilead ’s Harvoni and Sovaldi Demonstrate Efficacy and Safety among Chronic Hepatitis C Patients with Advanced Liver Disease

    Gilead ’s Harvoni and Sovaldi Demonstrate Efficacy and Safety among Chronic Hepatitis C Patients with Advanced Liver Disease

  4. Merck says experimental Hepatitis C treatment shows 95% cure rate

    Merck says experimental Hepatitis C treatment shows 95% cure rate

  5. MARKET SNAPSHOT: Apple, Energy, Health Care Earnings To Dominate Week

    MARKET SNAPSHOT: Apple, Energy, Health Care Earnings To Dominate Week

  6. UPDATE: Apple, energy, health care earnings to dominate week

    UPDATE: Apple, energy, health care earnings to dominate week

  7. Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide for HIV Treatment

    Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide for HIV Treatment

  8. AbbVie Hepatitis C Drug Granted Priority FDA Review

    AbbVie Hepatitis C Drug Granted Priority FDA Review

  9. Nasdaq Composite Rises Above March 2000 Record Close

    Nasdaq Composite Rises Above March 2000 Record Close

  10. Medivir: Data from OPTIMIST trials show SVR12 rates of 97 percent in HCV patients without cirrhosis and 84 percent in HCV patients with cirrhosis

    Medivir: Data from OPTIMIST trials show SVR12 rates of 97 percent in HCV patients without cirrhosis and 84 percent in HCV patients with cirrhosis

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.